Drugs / Rostafuroxin
Rostafuroxin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03217825 | Dec 2015 → Feb 2018 | essential hypertension | Windtree Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01320397 | May 2011 → Jul 2012 | essential hypertension | RostaQuo S.p.A. | Unknown | No outcome recorded |
| Phase 2 | NCT00415038 | Feb 2005 → Apr 2007 | essential hypertension | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rostafuroxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01320397 ↗ |
| Known as | Rostafuroxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2068971 ↗ |
| Known as | Rostafuroxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2068971 ↗ |
| Action | Inhibit | “which selectively antagonizes the effects of endogenous ouabain (EO) on Na+,K+-ATPase and mutated adducin” PMID 21235787 ↗ Jan 2011 |
| Modality | Small molecule | “rostafuroxin, a digitoxygenin derivative” PMID 21235787 ↗ Jan 2011 |
| Route | Oral | “The antihypertensive effect of rostafuroxin is long-lasting since it is still present 24 hours after oral administration” NCT01320397 ↗ |